| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 |
| filingDate |
2009-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8249b486d81d0032e841c96866f86fbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1acc40e1682f15adc85feb82d8f19e4 |
| publicationDate |
2011-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011045508-A1 |
| titleOfInvention |
Urinary CA125 Peptides as Biomarkers of Ovarian Cancer |
| abstract |
The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8476026-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009075305-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011028343-A1 |
| priorityDate |
2008-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |